Korio’s Next-Generation RTSM Platform Selected for The Leukemia & Lymphoma Society’s Beat AML Master Clinical Trial


DOYLESTOWN, PA — Korio, Inc. announced its collaboration with The Leukemia & Lymphoma Society (LLS) on its innovative  Beat AML® Master Clinical Trial. Beat AML® is the first collaborative precision medicine clinical trial for a blood cancer, using cutting-edge genomic technology to match patients to the most promising targeted treatment for their acute myeloid leukemia (AML).

LLS selected Korio as its RTSM provider to support patient enrollment and randomization for its first randomized sub-study in the trial. Within trials, sponsors, contact research organizations (CROs) and clinical trial site personnel have numerous systems to interact with while treating patients. The RTSM platform will provide a more streamlined user experience for patient enrollment and sub study randomization under a complex umbrella trial protocol. Korio’s suite of best-in-class IRT (interactive response technology) functionality is nested in a comprehensive GxP framework to produce high-quality results.

“Combining Korio’s platform with the incredible work currently in progress for Beat AML® will enhance integration across its many partners, leveraging technology to support the discovery of promising new AML therapies,” said Ryan Keane, Co-founder and CEO of Korio. “We are honored that LLS, the global leader in creating a world without blood cancer has partnered with us to help achieve their mission.”

LLS has assembled an impressive network of Beat AML® partners, including the U.S. Food & Drug Administration (FDA), top cancer centers, multiple pharmaceutical companies, a CRO, and select technology experts, who have united to find cures for AML.

“Innovative technology is critical to the success of the Beat AML® Master Clinical Trial,” said Len Rosenberg, PhD, RPh, Head of Clinical Operations at LLS. “As we continue to work towards better outcomes for patients through innovation including technology adoption, we are confident that our sites and patients will benefit greatly from Korio’s streamlined experience.”

READ:  NEXGEL to Participate in the LD Micro Invitational XIII on June 6th

For more information on the Beat AML® Master Clinical Trial, visit www.lls.org/beataml.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.